DUBLIN--(BUSINESS WIRE)--The "Global Human Immunodeficiency Virus (HIV) Market: Industry Analysis & Outlook (2017-2021)" report has been added to Research and Markets' offering.
"Global HIV Market: Industry Analysis & Outlook (2017-2021)" provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S along with the global market.
HIV therapeutics market is likely to witness a growth with increasing demand for single tablet regimens and growth of HIV diagnostic market is expected to be driven by increasing technological advancements in diagnosis tests.
Middle East and Africa are the major contributors to the global HIV market supported by increased prevalence of HIV due to rising drug abuse and unprotected physical contacts among adolescents. Asia-Pacific is likely to experience further growth of HIV market due to recent development in HIV treatments.
The global HIV market is expected to grow in future due to decreasing HIV related death rates, low awareness of HIV transmission and government initiatives to promote HIV treatment. Key trends of this market include progressing HIV drug under pipeline, increasing adoption of STR and Development of technologically advanced diagnostic products. However, there are some factors which can hinder growth of the market including decreasing global HIV funds, social stigma and discrimination and treatment failures.
The report profiles players of the market including Johnson & Johnson, Merck and Co., Gilead and GlaxoSmithKline Plc.
Key Topics Covered:
1. Overview
2. Global HIV Market
3. Regional HIV Market
4. Market Dynamics
5. Competition
6. Company Profiles
- Gilead
- GlaxoSmithKline Plc.
- Johnson & Johnson
- Merck & Co.
For more information about this report visit https://www.researchandmarkets.com/research/ctmrjj/global_human
